石藥集團(1093.HK)大跌8% 網傳重磅品種進入第三輪藥品帶量採購目錄
格隆匯11月29日丨港股大跌,醫藥板塊重挫,其中,石藥集團(1093.HK)跳空大跌8.21%,報18.12港元,創1個月新低。完成第一輪“4+7”城市試點及第二輪全國擴圍的談判之後,第三輪藥品帶量採購已經到來。據悉,目前國家組織藥品集中採購和使用聯合採購辦公室已要求各地醫療保障局報送第三輪擬集採品種的相關數據,涉及產品共35個,包括阿卡波糖片、阿比特龍、安利生坦片阿德福韋酯片、阿奇黴素片、阿莫西林片等。網傳石藥集團的注射用紫杉醇(白蛋白結合型)進入第三輪藥品帶量採購目錄。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.